key: cord-0826541-phncq32k
authors: Lacroix, Matthew; Uebbing, Emily; Bratberg, Jeffrey; Federico, Christopher
title: Pharmacists’ Response During a Pandemic: A Survey on Readiness to Test During COVID19
date: 2020-10-12
journal: J Am Pharm Assoc (2003)
DOI: 10.1016/j.japh.2020.10.003
sha: 9eb490bce9ae7a1c797b481c7e17e9f1b063c4c2
doc_id: 826541
cord_uid: phncq32k

Background Testing is a principle component to reopening society and bringing the coronavirus pandemic to an end. Pharmacists have the ability to perform certain point-of-care tests under federal regulations. On April 8, 2020, the Office of the Assistant Secretary for Health (OASH) issued new guidance authorizing licensed pharmacists to order and administer COVID-19 tests. Objective The primary objective of this study was to investigate the views of pharmacists about pharmacist- ordered and administered COVID-19 testing. Methods A 13-item questionnaire was developed to survey pharmacists who currently hold an active license in Rhode Island. Results One hundred and twenty-two pharmacists (13.8%) consented and responded to at least one question of the survey. The results indicated that the primary concern of pharmacists in regard to performing COVID-19 testing was spreading the infection to family members (71.3%). Becoming personally infected (59.8%) and not having access to appropriate personal protective equipment (PPE) (62.3%) were the second and third most common concern of pharmacists. Almost all pharmacists (99.9%) responded that they would be willing to take part in the testing process if they had appropriate PPE. Forty-six percent of pharmacists expressed concern regarding reimbursement for their company while 56% of pharmacists requested personal compensation for this service. Discussion Expanding the pool of healthcare professionals who can perform testing is critical to achieving and sustaining proposed testing thresholds. Rhode Island pharmacists are willing to take part in performing COVID-19 testing, provided appropriate PPE is available and services are reimbursed.Pharmacists are the most accessible and essential healthcare providers willing to take on critically important roles during the COVID19 pandemic, provided appropriate safety measures can be met.

J o u r n a l P r e -p r o o f

Testing is a principle component to reopening society and bringing the coronavirus 5

pandemic to an end. Pharmacists have the ability to perform certain point-of-care tests 6 under federal regulations. On April 8, 2020, the Office of the Assistant Secretary for Health 7

(OASH) issued new guidance authorizing licensed pharmacists to order and administer 8 COVID-19 tests. 9 10

Objective 11

The primary objective of this study was to investigate the views of pharmacists about 12

pharmacist-ordered and administered COVID-19 testing. 13

A 13-item questionnaire was developed to survey pharmacists who currently hold an 15 active license in Rhode Island. 16

One hundred and twenty-two pharmacists (13.8%) consented and responded to at least 18 one question of the survey. The results indicated that the primary concern of pharmacists 19

in regard to performing COVID-19 testing was spreading the infection to family members 20 (71.3%). Becoming personally infected (59.8%) and not having access to appropriate 21 personal protective equipment (PPE) (62.3%) were the second and third most common 22

concern of pharmacists. Almost all pharmacists (99.9%) responded that they would be 23 willing to take part in the testing process if they had appropriate PPE. Forty-six percent of 24

pharmacists expressed concern regarding reimbursement for their company while 56% of 25

pharmacists requested personal compensation for this service. 26

Expanding the pool of healthcare professionals who can perform testing is critical to 28 achieving and sustaining proposed testing thresholds. Introduction 21 22

The first case of the novel coronavirus, SARS-CoV-2, was reported in the United 23

States (U.S) on January 19, 2020, and by October 3 rd , 2020, there were over 7.3 million 24 cases in the U.S accounting for over 205,000deaths. 1,2 Similar to influenza, SARS-CoV-2 25

transmits primarily through respiratory droplets. 3 Although young healthy people can be 26

infected, develop critical illness, and die, the majority of death from the virus occurs in 27 older people with underlying conditions such as cardiovascular disease. 4 What may be the 28 most dangerous aspect of SAR2-CoV-2 and subsequent COVID-19 infection, is 29 asymptomatic and pre-symptomatic transmission spread. 5 Symptoms develop between 30 two to fourteen days after exposure, which allows for transmission of the disease without 31 the vector's knowledge 6 Healthcare professionals and leaders need to take a unique 32 approach in identifying opportunities for early screening and mitigating risk of widespread 33 infection transmission. 7,8 34 35

The period of COVID-19 infection without symptoms leaves individuals and the 36 healthcare community uninformed, posing the greatest risk for transmission of disease. 37

Allowing anyone to obtain a COVID-19 test by removing barriers to testing, leads to quicker 38 isolation, contact tracing, and quarantine. The United States does not have a unified 39 national testing infrastructure, leaving decisions on testing to states. 9 This has led to 40 widespread logistical and operational problems with acquisition of limited supplies of 41 testing equipment and reagents, slowing the delivery of results. As of this writing, the US 42 leads the world in per capita cases, hospitalizations, and deaths. 1 Still, governors across the 43 U.S. have developed systematic, evidence-based approaches to testing and other harm 44 reduction approaches like masking, hand hygiene, and social distancing, that have allowed 1 some states to re-open their economies. The success and execution of these plans, including 2

Rhode Island's, is dependent on testing. 9,10 3 4

Pharmacy practice continues to fill gaps in health care and population health to 5 address unmet patient needs. Most households in the U.S. are within 5 miles of a pharmacy 6 and more than one pharmacist. 11 Patients access pharmacists significantly more frequently 7 than their primary care providers. 12 Community pharmacy-based point of care testing 8

(POCT) is one way pharmacists can improve and expand accessibility to services otherwise 9

not readily available to their patients. The Clinical Laboratory Improvement Amendments 10 of 1988 (CLIA) included pharmacies as laboratories, giving them the authorization to 11

perform point of care tests, in accordance with state and federal regulations. Requirements 12

for these tests vary state to state and include 120 low-risk tests, including dyslipidemia, 13

diabetes, influenza and streptococcus Group A. 13 As of July 20, 2020, over 14,000 14

pharmacies have been issued a CLIA waiver to perform POCT. 14 15 16

On The primary objective of this study is to investigate the views of pharmacists on 45

pharmacist-ordered and administered COVID-19 testing.

Methods 3 4 5

Study design, population and setting 6 7

This was a descriptive survey study that was approved as exempt by the University 8

of Rhode Island IRB. 9

Pharmacists who had email addresses publicly listed with the Rhode Island Department of 10

Health received an email asking them to complete a survey. The professional associations 11 disseminated the study as follows: April 30 th the original message was sent to all 12

pharmacists, May 1 st , the survey was advertised via an electronic newsletter, and on May 13 7 th , a reminder was sent via the association list serve. participants could select more than one answer for seven questions.

The thirteen-question anonymous survey was designed by study personnel to take 33 less than 10 minutes to complete. Questions and elements were created and written by 34 study personnel collectively. The survey was not piloted nor validated. Participants were 35

able to quit the survey at any time without recording any information. All responses were 36 stored within the Qualtrics (Qualtrics, Provo, UT) survey system and were only accessed by 37 the researchers for analyses. 38 39 40

Results 41

A total of 879 pharmacists received an email asking them to complete the survey 42

and 142 pharmacists agreed to take part in the study. One hundred and twenty-two 43

pharmacists (13.8%) consented and responded to at least one question. Ninety-three 44 (76.2%) pharmacists described RI as their primary practice location, 33 (22.9%) indicated 45 chain community pharmacy as their primary practice site, and 72 pharmacists (59%) 1 graduated pharmacy school before 2005. Table 1 shows all the responses to each question 2 on the survey. The primary concern with COVID-19 testing was infecting family members 3 from work exposure expressed by 87 (71.3%) pharmacists. If asked to conduct COVID- 19 4 testing, 63 pharmacists (51.6%) felt they would not have access to appropriate PPE if they 5

were to conduct testing. Forty-six pharmacists (37.7%), indicated that their practice site 6

could not be made safe through modifications for testing. 7

One hundred and four pharmacists (90.0%) were willing to participate in COVID-19 testing 8 through receiving patient collected samples, collecting samples, ordering tests, selling at 9

home tests, and/or analyzing specimen brought in by a patient. State run testing centers 10 was the preferred testing location among pharmacists (70.5%). Twenty-one pharmacists 11

(17.2%) indicated that they would not feel comfortable performing COVID-19 testing in 12 any setting and 7 pharmacists (1.94%) indicated that they would not feel comfortable with 13

any role involved in COVID-19 testing.. Pharmacists felt most comfortable collecting nasal 14

(75.4%), saliva (73.0%) and finger stick (60.7%) samples. Collecting samples from patients 15

which are not routinely used in community practice were less preferred. Ultimately, 85% of 16

pharmacists were comfortable with collecting a sample from at least one of the available 17 methods. 18

One hundred and twenty-one (99.2%) pharmacists would consider ordering and 19

administering COVID-19 tests if reimbursement were provided, either personally or for 20 their employer. Receiving additional live, instructor-led, training for collection and 21

administration of COVID-19 tests, was rated as the second most important item. When 22

training and reimbursement were taken into consideration, 81 (66.4%) pharmacists 23

preferred appointment based testing to on-demand testing. 24

This study indicated that the majority of pharmacists were willing to perform COVID- 19 26 testing. Only a small percentage (9%) of survey pharmacists indicated that they would not 27 be willing to perform COVID-19 tests even if it was required by their employer. The results 28 from this study portray willingness of pharmacists to participate in COVID-19 testing 29 efforts given certain measures can be met. 30

The most common concerns reported among pharmacists were bringing home the 31 infection to family members, not having adequate PPE, and getting personally infected. responses. Several individuals who were invited to partake in the survey do not work in 18 direct patient care and did not complete the survey due to the feeling that the survey was 19 not aimed at them, even though the investigators were looking to collect information from 20 all licensed individuals. 21

Expanding the pool of healthcare professionals who can perform testing is critical to 23 achieving and sustaining proposed testing thresholds. Rhode Island pharmacists are willing 24 to take part in performing COVID-19 testing, provided appropriate PPE is available and 25 services are reimbursed. 26 27 

Johns Hopkins Coronavirus Resource 28 Center

COVID-19) -Transmission. Centers for Disease 32 Control and Prevention

Clinical Characteristics of 138 Hospitalized Patients With 36 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

The implications of silent transmission for 39 of COVID-19 outbreaks

The Incubation Period of Coronavirus Disease 2019 3 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

Testing for COVID-19: A way to lift confinement restrictions

COVID National Diagnostics Strategy 05 24 2020 v FINAL.pdf. Accessed

RI.gov: Rhode Island Government

The availability of 18 pharmacies in the United States

Evaluation of Frequency of 21 Encounters With Primary Care Physicians vs Visits to Community Pharmacies Among 22

Medicare Beneficiaries

Pharmacy-Based Infectious Disease Management 25

Programs Incorporating CLIA-Waived Point-of-Care Tests

Division N. HHS Statements on Authorizing Licensed Pharmacists to Order and 30

Administer COVID-19 Tests. HHS.gov. Published

Public Health Management of Healthcare Workers Exposed to or with Suspected or 35

Centers for Disease Control and 36 Prevention

Infection prevention and control during health care when novel coronavirus (nCoV) 40 infection is suspected

COVID-19). Guidance for Pharmacists and Pharmacy 43 Technicians in Community Pharmacies during the COVID-19 Response

Disease Control and Prevention

Pharmacists Concerned About Lack of Personal Protective Equipment, Hand Sanitizers 1 for COVID-19 Outbreak

A prospective cohort study in non-hospitalized 5 household contacts with SARS-CoV-2 infection: symptom profiles and symptom 6 change over time

Household Transmission of SARS-CoV-2 from 9 Adults to Children

Secondary Attack Rate of COVID-19 in household 12 contacts: Systematic review

Mental health issues impacting 15 pharmacists during COVID-19

Nasal Swab Sampling for SARS-CoV-2: a Convenient 18

Alternative in Times of Nasopharyngeal Swab Shortage